A study presented at the European Lung Cancer Congress investigated the effects of multiple therapies on symptom management in ALK-positive non-small cell lung cancer. READ MORE
Elderly lung cancer patients who are black or from less educated communities are less likely to get the combination of chemotherapy and radiation that’s linked to better survival odds.
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.
A recent study identified substantial barriers to standard-of-care therapy for limited-stage small cell lung cancer, including government insurance coverage.
Adjuvant EGFR TKI treatment for patients with EGFR-mutant NSCLC after complete resection offers a significant disease-free survival advantage, according to a recent meta-analysis.